Bryn Mawr Capital Management LLC Invests $213,000 in Teleflex Incorporated (NYSE:TFX)

Bryn Mawr Capital Management LLC acquired a new position in shares of Teleflex Incorporated (NYSE:TFX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,196 shares of the medical technology company’s stock, valued at approximately $213,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Avior Wealth Management LLC boosted its stake in shares of Teleflex by 190.6% during the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock worth $38,000 after acquiring an additional 101 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in Teleflex during the third quarter worth $40,000. True Wealth Design LLC grew its holdings in Teleflex by 16,600.0% in the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 166 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Teleflex in the third quarter valued at $54,000. Finally, Banque Cantonale Vaudoise raised its stake in shares of Teleflex by 184.8% during the 3rd quarter. Banque Cantonale Vaudoise now owns 225 shares of the medical technology company’s stock worth $56,000 after buying an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 21.8 %

TFX stock opened at $138.99 on Friday. The company has a 50 day moving average price of $176.35 and a two-hundred day moving average price of $205.70. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The stock has a market capitalization of $6.46 billion, a P/E ratio of 27.63, a PEG ratio of 1.73 and a beta of 1.16. Teleflex Incorporated has a one year low of $135.95 and a one year high of $249.90.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. The business had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. As a group, sell-side analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.98%. Teleflex’s dividend payout ratio is currently 27.04%.

Analyst Ratings Changes

A number of equities research analysts recently commented on TFX shares. Citizens Jmp cut shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Mizuho reduced their target price on Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. StockNews.com raised Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Finally, Royal Bank of Canada reduced their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $246.00.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.